Menu
Back to Journals » International Journal of Nanomedicine » Volume 16
Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment
Authors Li C, Wan L, Luo J, Jiang M, Wang K
Received 24 September 2020
Accepted for publication 9 January 2021
Published 17 February 2021 Volume 2021:16 Pages 1261—1280
DOI https://doi.org/10.2147/IJN.S283416
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Prof. Dr. Thomas J. Webster
Chen Li1 12 2,* Long Wan1 12 2,* Jie Luo1 12 2, Mingyan Jiang1 12 2, Keke Wang1 12 2
1Department of Pharmacy, The First Hospital of China Medical University, Shenyang, 110001, Liaoning, People’s Republic of China; 2School of Pharmacy, China Medical University, Shenyang, 110122, Liaoning, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Keke Wang
Department of Pharmacy, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang, 110001, Liaoning, People’s Republic of China
Tel +86-24-83282662
Email wkkcc@163.com
Abstract: Diabetes mellitus is a major threat to human health. Both its incidence and prevalence have been rising steadily over the past few decades. Biomacromolecular agents such as insulin and glucagon-like peptide 1 receptor agonists are commonly used hypoglycemic drugs that play important roles in the treatment of diabetes. However, their traditional frequent administration may cause numerous side effects, such as pain, infection or local tissue necrosis. To address these issues, many novel subcutaneous delivery systems have been developed in recent years. In this review, we survey recent developments in subcutaneous delivery systems of biomacromolecular hypoglycemic drugs, including sustained-release delivery systems and stimuli-responsive delivery systems, and summarize the advantages and limitations of these systems. Future opportunities and challenges are discussed as well.
Keywords: diabetes mellitus, subcutaneous injection, insulin, glucagon-like peptide 1 receptor agonists, sustained-release, stimuli-responsive
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.